Dr. Mellinghoff is a physician-scientist developing molecularly targeted therapies for cancer through the study of signaling pathways in experimental models, examination of patient-derived biospecimen, and early-phase clinical trials.
Our research focuses on molecular mechanisms that regulate cancer growth and drug response. Our long-term goal is to develop therapeutic paradigms that target specific properties of primary brain tumors, including genetic and epigenetic alterations in cancer signaling pathways, unique aspects of brain tumor metabolism, or interactions of brain tumor cells with their brain microenvironment. Our studies in laboratory models and patient-derived biospecimen are closely linked to the evaluation of molecularly targeted agents in clinical trials.
Biography
Dr. Mellinghoff is a Neuro-Oncologist and Chair of the Department of Neurology at Memorial Sloan Kettering Cancer Center. He completed his training at the Technical University of Munich (TUM) and the University of California, Los Angeles (UCLA). His research has advanced the development of molecularly targeted agents for cancer, including inhibitors of mutant isocitrate dehydrogenase, the epidermal growth factor receptor, and Bruton Tyrosine Kinase. Dr. Mellinghoff is an elected member of the American College of Physicians and serves as advisor to many entities in the public or private sector.
Distinctions:
Neuro-Oncology Scientific Award, American Academy of Neurology (2023)
Member, Association of American Physicians (2020)
Member, American Society of Clinical Investigation (2013)
